trending Market Intelligence /marketintelligence/en/news-insights/trending/j2LhEJFJxrGNP2rIkjax8w2 content esgSubNav
In This List

US FDA extends review of Flexion's osteoarthritis knee pain drug Zilretta

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


US FDA extends review of Flexion's osteoarthritis knee pain drug Zilretta

The U.S. Food and Drug Administration needs more time to review Flexion Therapeutics Inc.'s supplemental new drug application for Zilretta beyond the expected Oct. 14 decision date.

Zilretta was approved to treat osteoarthritis knee pain in 2017. The Burlington, Mass.-based biotechnology company has asked the FDA to revise Zilretta's label to include results from a Phase 3b clinical trial that evaluated repeated doses of the drug in patients with osteoarthritis knee pain.

The regulator did not provide a new date for the decision, but said the review is expected to be completed in the next few weeks, according to Flexion's Oct. 14 press release. Flexion also said the agency has not asked for any additional information to supplement the application.

Flexion develops anti-inflammatory and pain management therapies for patients with musculoskeletal conditions.